OPPORTUNITIES FOR HIGH-COST DRUGS IN INDIA

被引：0
|
作者：
Ramabadran, A. [1 ]
Samuel, J. J. [2 ]
Edathodu, A. [2 ]
Mukku, S. R. [2 ]
机构：
[1] Univ Cambridge, Cambridge, England
[2] Access Infin Ltd, London, England
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN240
引用
收藏
页码：A131 / A131
页数：1
相关论文
共 50 条
  • [31] Expenditures of the Ministry of Health of Brazil with high-cost drugs: A Patient-Centered Analysis
    Ruas Brandao, Cristina Mariano
    Guerra Junior, Augusto Afonso
    Cherchiglia, Mariangela Leal
    Gurgel Andrade, Eli Iola
    Almeida, Alessandra Maciel
    da Silva, Grazielle Dias
    de Queiroz, Odilon Vanni
    Faleiros, Daniel Resende
    Acurcio, Francisco de Assis
    VALUE IN HEALTH, 2011, 14 (05) : S71 - S77
  • [32] Financing Strategies to Facilitate Access to High-Cost Anticancer Drugs: A Systematic Review of the Literature
    Patikorn, Chanthawat
    Taychakhoonavudh, Suthira
    Sakulbumrungsil, Rungpetch
    Ross-Degnan, Dennis
    Anantachoti, Puree
    INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2022, 11 (09) : 1625 - 1634
  • [33] GLOBAL TRENDS IN ALTERNATIVE ACCESS ARRANGEMENTS FOR HIGH-COST ONCOLOGY AND RARE DISEASE DRUGS
    Nash, C.
    Kunitskaya, A.
    Duttagupta, S.
    VALUE IN HEALTH, 2020, 23 : S252 - S252
  • [34] Evolution of reimbursement of high-cost anticancer drugs: Financial impact within a university hospital
    Baudouin, Amandine
    Fargier, Emilie
    Cerruti, Ariane
    Dubromel, Amelie
    Vantard, Nicolas
    Ranchon, Florence
    Schwiertz, Verane
    Salles, Gilles
    Souquet, Pierre-Jean
    Thomas, Luc
    Berard, Frederic
    Nancey, Stephane
    Freyer, Gilles
    Trillet-Lenoir, Veronique
    Rioufol, Catherine
    BULLETIN DU CANCER, 2017, 104 (06) : 538 - 551
  • [35] Navigating high-cost medicines: summary of the Guiding Principles for the governance of high-cost medicines in Australian hospitals
    Hill, Catherine L.
    Pulver, Lisa K.
    Liew, David F. L.
    INTERNAL MEDICINE JOURNAL, 2024, 54 (10) : 1733 - 1738
  • [36] The Challenge of Sustainability of High-Cost Oncological Drugs: A Budgeting Model in an Italian Cancer Center
    Masini, Carla
    Gallegati, Davide
    Gentili, Nicola
    Massa, Ilaria
    Ciucci, Raffaella
    Altini, Mattia
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (24)
  • [37] Introduction: Off-Label Uses and High-Cost Drugs: Promotion and Reimbursement Issues
    Sheila R. Shulman
    Drug information journal : DIJ / Drug Information Association, 1998, 32 (2): : 363 - 365
  • [38] IMPACT OF PATIENT REPORTED OUTCOMES ON MEDICATION THERAPY MANAGEMENT FOR HIGH-COST SPECIALTY DRUGS
    Feinberg, B. A.
    Burruss, R.
    Traurig, T.
    Drenning, J.
    VALUE IN HEALTH, 2015, 18 (03) : A262 - A262
  • [39] STRATEGIES TO IMPROVE ACCESS TO HIGH-COST ANTICANCER DRUGS: LESSONS LEARNED FOR ASEAN COUNTRIES
    Patikorn, C.
    Taychakhoonavudh, S.
    Anantachoti, P.
    VALUE IN HEALTH, 2018, 21 : S20 - S21
  • [40] Introduction: Off-label uses and high-cost drugs: Promotion and reimbursement issues
    Shulman, SR
    DRUG INFORMATION JOURNAL, 1998, 32 (02): : 363 - 365
12345